Neurological Biomarkers Market Report by Type (Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers, and Others), Application (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorders, and Oth

Neurological Biomarkers Market Report by Type (Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Imaging Biomarkers, and Others), Application (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorders, and Others), End Use (Hospital Laboratories, Clinical Diagnostic Centers, Research Organizations, and Others), and Region 2024-2032

The global neurological biomarkers market size reached US$ 8.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 24.0 Billion by 2032, exhibiting a growth rate (CAGR) of 11.3% during 2024-2032.

Neurological biomarkers are molecules present in the blood or cerebral spinal fluid (CSF) that support the diagnosis of brain disorders and monitor disease progression. The main sources of these biomarkers are genetic mutations, metabolite levels, brain imaging and changes in protein expression or post-translational modifications. As they detect biological responses to experimental drugs and aid in discovering new targets for therapeutic intervention, neurological biomarkers are widely used in clinical practice during drug development. Presently, researchers measure biomarker concentrations to provide non-invasive testing, earlier diagnosis and personalized treatments.

The rising occurrence of neurological disorders, such as stroke, motor neuron disease (MND), Alzheimer’s disease (AD), Parkinson’s disease (PD) and Huntington’s disease (HD), is escalating the need for faster drug development. This represents one of the primary factors impelling the market growth as biomarkers help measure the efficacy of new drugs and therapeutic strategies. The increasing adoption of minimally invasive procedures and personalized medicines are acting as another major growth-inducing factor. Apart from this, as various neurological disorders share standard features, there is an increase in the demand for multiple biomarkers to differentiate specific diseases and their sub-types. Moreover, advancements in mass spectrometry and imaging procedures enable faster evaluation of large numbers of biochemical markers and structural changes in the brain. This, along with the introduction of digital biomarkers and the rising number of clinical trials, is anticipated to propel the growth of the market in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global neurological biomarkers market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, application and end use.

Breakup by Type:

• Genomic Biomarkers
• Proteomic Biomarkers
• Metabolomic Biomarkers
• maging Biomarkers
• Others

Breakup by Application:

• Alzheimer's Disease
• Parkinson's Disease
• Multiple Sclerosis
• Autism Spectrum Disorders
• Others

Breakup by End Use:

• Hospital Laboratories
• Clinical Diagnostic Centers
• Research Organizations
• Others

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Acumen Pharmaceuticals Inc., Athena Diagnostics (Quest Diagnostics), Banyan Biomarkers Inc., Bio-Rad Laboratories Inc., Immunarray Pvt. Ltd., Myriad Rbm Inc. (Myriad Genetics Inc.), Proteome Sciences Plc and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report:

• How has the global neurological biomarkers market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global neurological biomarkers market?
• What are the key regional markets?
• What is the breakup of the market based on the type?
• What is the breakup of the market based on the application?
• What is the breakup of the market based on the end use?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global neurological biomarkers market and who are the key players?
• What is the degree of competition in the industry?